English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The success of therapeutic advancements during the last decade have resulted in an increase in the number of cancer survivors, with now >14.5 million cases in the United States in 2016.1 However, this success has created a paradigm: cardiotoxicity and left ventricular (LV) dysfunction have become the most frequent adverse effects of cancer treatment regimens—especially anthracyclines—offsetting the benefits of these life-saving therapies. Navigating patients through cancer treatment while mitigating the development of LV dysfunction has become increasingly important.See Article by Farhad et al Traditionally, the most widely used strategies to detect cardiotoxicity included monitoring of LV ejection fraction (LVEF) by cardiac imaging or directly visualizing myocellular injury from right heart endomyocardial biopsies.2 Although histopathologic examinations are often revealing, their invasive nature and consequent associated risks favor the development of more suitable alternatives. Notably, the rapid evolution of noninvasive cardiac imaging strategies to monitor cardiac function is providing new opportunities for the early detection of LV dysfunction.Cardiovascular magnetic resonance (CMR) imaging is rapidly becoming a central diagnostic tool in cardiovascular medicine, not only because of its ability to provide accurate volumetric and functional systolic and diastolic function measurements of the ventricles, but also because of its unique ability to characterize myocardial tissue and, thereby, determine the pathogenesis of myocardial dysfunction.3 These features are particularly important in the cardio-oncology arena when trying to determine the pathogenesis of an LVEF decline in a patient treated for cancer that also exhibits several other cardiovascular comorbidities.CMR uses the tissue response of exposure to nonionizing electromagnetic radiation within magnetic fields to generate within the body contrast between different structures and tissues and, thereby, allowing the identification of abnormal pathology.4 Novel mapping techniques capture the evolution of T1 recovery within a single breath-hold, and if measured before and after the …

Is Myocardial Fibrosis a New Frontier for Discovery in Cardiotoxicity Related to the Administration of Anthracyclines?